Soriot discussed the impact of potential tariffs during a call on AstraZeneca's earnings. For the three months ended March 31, during which period the firm netted $13.59 billion in total revenue, an ...

Both gene therapies were approved as treatments for dystrophic epidermolysis bullosa, a rare and debilitating genetic skin condition.

Both gene therapies were approved as treatments for dystrophic epidermolysis bullosa, a rare and debilitating genetic skin condition.

During an earnings call, the firm reported strong sales for Pluvicto and other precision medicines and elaborated on its US manufacturing plans.

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

The RAS(ON) inhibitor shrunk tumors in around 60 percent of patients with KRAS G12D mutations, according to a study presented at AACR's annual meeting.

A trial by MSK researchers has shown that neoadjuvant treatment with GSK's Jemperli spared 80 percent of patients with dMMR ...

The model combines estimates of skeletal muscle with routinely collected clinical data and unstructured notes and predicts the individual likelihood of cachexia.

The UK-based company will evaluate BFB-101 in up to five children with hereditary spastic paraplegia type 47 in a Phase I/II trial.

In the study, patients with advanced solid tumors must be HLA-A*02:01 positive and harbor a p53 R175H mutation.

Leukemia patients who enroll in LLS's PedAL screening trial and are found to have certain alterations will be directed to receive ziftomenib in a Phase I study.

If the European Commission approves this treatment, it'll be the first HER2-targeted agent for HER2-positive biliary tract cancer available to patients in the EU.